Antibiotic Resistance in COPD Patients in the Intensive Care Unit: A Review of Recent Developments

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality globally, and it remains a leading contributor to hospital admissions, particularly in the elderly. In the past decade, COPD has been identified as one of the leading risk factors for infection-related complications, including pneumonia, bronchitis, and ventilator-associated pneumonia (VAP). Antibiotics are a cornerstone of therapy for COPD exacerbations caused by bacterial infections. However, inappropriate antibiotic use in this patient population has led to an increasing burden of antibiotic resistance. The overuse of broad-spectrum antibiotics is especially problematic in ICU settings, where empirical antibiotic treatment is often initiated without adequate microbiological testing. The relationship between COPD and antibiotic resistance is multifaceted. On the one hand, COPD patients are more likely to require antibiotics due to recurrent infections, leading to frequent antibiotic courses. On the other hand, the repeated exposure to antibiotics can promote the selection of resistant bacterial strains. The management of antibiotic resistance in COPD patients, particularly those in the ICU, is a complex and growing challenge. Strategies such as antibiotic stewardship programs, rapid microbiological diagnostics, and the use of narrow-spectrum antibiotics have been shown to reduce the emergence of resistant organisms and improve patient outcomes. However, the problem of antibiotic resistance in COPD patients remains significant, particularly in the context of multidrug-resistant pathogens.

Keywords

• intensive care unit
• chronic obstructive pulmonary disease
• antibiotic resistance

References

1. 1. Hanania NA. Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Respir Med. 2012;106(2):S1-2.
2. 2. MacLeod M, Papi A, Contoli M, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. Respirology. 2021;26(6):532-51.
3. 3. Bajire SK, Shastry RP. Synergistic effects of COVID-19 and Pseudomonas aeruginosa in chronic obstructive pulmonary disease: a polymicrobial perspective. Mol Cell Biochem. 2024;479(3):591-601.
4. 4. Herath SC, Normansell R, Maisey S, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018 30;10(10):CD009764.
5. 5. Nseir S, Di Pompeo C, Cavestri B, et al. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome. Crit Care Med. 2006;34(12):2959-66.
6. 6. Kaleem Ullah M, Malamardi S, Siddaiah JB, et al. Trends in the Bacterial Prevalence and Antibiotic Resistance Patterns in the Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Hospitalized Patients in South India. Antibiotics (Basel). 2022;11(11):1577.
7. 7. Abdelsalam Elshenawy R, Umaru N, Aslanpour Z. Shorter and Longer Antibiotic Durations for Respiratory Infections: To Fight Antimicrobial Resistance-A Retrospective Cross-Sectional Study in a Secondary Care Setting in the UK. Pharmaceuticals (Basel). 2024;17(3):339.
8. 8. van der Bie S, Haaksma ME, Vermin B, et al. A Systematic Review of the Pulmonary Microbiome in Patients with Acute Exacerbation COPD Requiring ICU Admission. J Clin Med. 2024;13(2):472.

9. 9. Suzuki A, Yamaguchi F, Maeda M, et al. Antimicrobial Stewardship Program for Patients in the Hematological Department Receiving Carbapenem Therapy: A Single-Center and Interrupted Time Series Analysis. Antibiotics (Basel). 2023;12(2):302.
10. 10. Li YJ, Pan CZ, Fang CQ, Zhao ZX, Chen HL, Guo PH, Zhao ZW. Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: genetic relationships, risk factors and mortality. BMC Infect Dis. 2017;17(1):371.
11. 11. Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med. 2020;46(5):888-906.
12. 12. Tavares LP, Galvão I, Ferrero MR. Novel Immunomodulatory Therapies for Respiratory Pathologies. Comprehensive Pharmacol. 2022:554–94.
13. 13. Joean O, Welte T. Vaccination and modern management of chronic obstructive pulmonary disease - a narrative review. Expert Rev Respir Med. 2022;16(6):605-14.